United Therapeutics Surges 4.16% on $1B Share Buyback as $350M Volume Ranks 346th in Market Activity

On August 5, 2025, United Therapeutics (UTHR) closed with a 4.16% gain, with trading volume reaching $350 million—a 30.84% increase from the prior day—ranking 346th in market activity. The stock’s performance followed key corporate developments and earnings updates.

The company announced a $1 billion accelerated share repurchase (ASR) program with Citibank, executed under a board-authorized initiative. This move, disclosed on July 30, signals strong capital allocation confidence amid ongoing revenue growth. Second-quarter financial results showed total revenue of $798.6 million, up 12% year-over-year, driven by increased sales of Tyvaso DPI, Nebulized Tyvaso, Orenitram, and Unituxin. However, earnings per share (EPS) fell short of estimates, with GAAP profit at $6.41 per share, 6.9% below analyst expectations.

Analysts highlighted the mixed performance, noting that while revenue growth outperformed forecasts, EPS misses raised concerns. Leerink Partners maintained a Buy rating with a $408 price target, citing the company’s long-term stability and pipeline advancements. Morgan Stanley adjusted its price target to $328 from $348 but retained an Equal Weight rating, reflecting broader sector headwinds. The UKidney human trial launch and Phase 3 enrollment completion for PAH drug Ralinepag further underscored the company’s focus on innovation and unmet medical needs.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day delivered a 166.71% return from 2022 to the present, outperforming the benchmark return of 29.18% by 137.53%. This underscores the role of liquidity concentration in short-term stock performance, particularly in volatile markets.